Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV-associated lower respiratory tract infection (LRTI) in infants. In August 2023, the Food and Drug Administration (FDA) approved R...

Full description

Saved in:
Bibliographic Details
Published in:MMWR. Morbidity and mortality weekly report 2023-10, Vol.72 (41), p.1115-1122
Main Authors: Fleming-Dutra, Katherine E, Jones, Jefferson M, Roper, Lauren E, Prill, Mila M, Ortega-Sanchez, Ismael R, Moulia, Danielle L, Wallace, Megan, Godfrey, Monica, Broder, Karen R, Tepper, Naomi K, Brooks, Oliver, Sánchez, Pablo J, Kotton, Camille N, Mahon, Barbara E, Long, Sarah S, McMorrow, Meredith L
Format: Article
Language:English
Subjects:
Advisory Committees
Communicable Diseases
COVID-19 vaccines
Disease prevention
Disease transmission
Diseases
Drug approval
Drug dosages
Economic impact
Epidemiology
FDA approval
Female
France
Full Report
Gestation
Hospitalization
Humans
Hypertension
Immunization
Infant
Infants
Pandemics
Pediatrics
Pharmaceutical industry
Preeclampsia
Pregnancy
Pregnant women
Premature birth
Prevention
Public health
Respiratory syncytial virus
Respiratory Syncytial Virus Infections - epidemiology
Respiratory Syncytial Virus Infections - prevention & control
Respiratory Syncytial Virus Vaccines
Respiratory Syncytial Virus, Human
Respiratory tract
Respiratory tract diseases
Respiratory tract infection
Respiratory Tract Infections - epidemiology
Respiratory Tract Infections - prevention & control
Seasons
United Kingdom
United States
United States - epidemiology
Vaccination
Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV-associated lower respiratory tract infection (LRTI) in infants. In August 2023, the Food and Drug Administration (FDA) approved RSVpreF vaccine (Abrysvo, Pfizer Inc.) for pregnant persons as a single dose during 32-36 completed gestational weeks (i.e., 32 weeks and zero days' through 36 weeks and 6 days' gestation) to prevent RSV-associated lower respiratory tract disease in infants aged
ISSN:0149-2195
1545-861X
DOI:10.15585/mmwr.mm7241e1